Comparative Study on the Efficacy of Liposomal Amphotericin B and Voriconazole in a Murine Pulmonary Aspergillosis Model

Background:No clinical studies have compared the efficacy of liposomal formulation AMB (L-AMB) and voriconazole (VRC) in the treatment of pulmonary aspergillosis. The aim of this study was to compare the efficacy of L-AMB and VRC in murine pulmonary aspergillosis.Methods: Leucopenic mice were infected intratracheally with Aspergillus fumigatus and treated intravenously with L-AMB (once a day) or VRC (twice a day). Results: L-AMB and VRC at a dose of ≥5 and ≥20 mg/kg, respectively, significantly prolonged the survival time of infected mice and reduced the pulmonary fungal burden in comparison with the control group. At the maximum recommended dose for clinical use, 5 mg/kg of L-AMB exhibited greater efficacy than 10 mg/kg of VRC, which achieved an area under the concentration-time curve level equivalent to that of 6 mg/kg (loading dose) in humans, in terms of increasing survival and reducing the fungal burden. Conclusion: The in vivo efficacy of L-AMB was superior to that of VRC at the maximum recommended dose in a murine pulmonary aspergillosis model.

[1]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  C. Heussel,et al.  Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Pemán,et al.  Epidemiology of invasive fungal infections due to Aspergillus spp. and Zygomycetes , 2006 .

[4]  Y. Ueda,et al.  Evaluation of Antifungal Pharmacodynamic Characteristics of AmBisome against Candida albicans , 2006, Microbiology and immunology.

[5]  Peter G. Pappas,et al.  Invasive Fungal Pathogens: Current Epidemiological Trends , 2006 .

[6]  Y. Ueda,et al.  Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis. , 2006, The Journal of antimicrobial chemotherapy.

[7]  T. Patterson,et al.  Sequential or Combination Antifungal Therapy with Voriconazole and Liposomal Amphotericin B in a Guinea Pig Model of Invasive Aspergillosis , 2006, Antimicrobial Agents and Chemotherapy.

[8]  D. Andes,et al.  Pharmacokinetic-Pharmacodynamic Comparison of Amphotericin B (AMB) and Two Lipid-Associated AMB Preparations, Liposomal AMB and AMB Lipid Complex, in Murine Candidiasis Models , 2006, Antimicrobial Agents and Chemotherapy.

[9]  Rachana Parmar,et al.  Comparative Efficacies of Conventional Amphotericin B, Liposomal Amphotericin B (AmBisome), Caspofungin, Micafungin, and Voriconazole Alone and in Combination against Experimental Murine Central Nervous System Aspergillosis , 2005, Antimicrobial Agents and Chemotherapy.

[10]  Steve A. Hernandez,et al.  Alternatives to amphotericin B for Candida rugosa infection. , 2004, The Journal of antimicrobial chemotherapy.

[11]  A. Nikolić,et al.  Combined Effect of Atovaquone and Pyrrolidine Dithiocarbamate in the Treatment of Acute Murine Toxoplasmosis , 2004, Chemotherapy.

[12]  Y. Hirakata,et al.  Pharmacodynamics and Bactericidal Activity of Gatifloxacin in Experimental Pneumonia Caused by Penicillin-Resistant Streptococcus pneumoniae , 2004, Chemotherapy.

[13]  N. Wood,et al.  The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. , 2003, British journal of clinical pharmacology.

[14]  D. Dunbar,et al.  Characterization of mouse small intestinal cytochrome P450 expression. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[15]  D. Andes,et al.  In Vivo Pharmacokinetics and Pharmacodynamics of a New Triazole, Voriconazole, in a Murine Candidiasis Model , 2003, Antimicrobial Agents and Chemotherapy.

[16]  M. Pfaller,et al.  Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi , 2003, Journal of Clinical Microbiology.

[17]  N. Wood,et al.  The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[18]  Richard Sylvester,et al.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.

[19]  Lawrence Corey,et al.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  D. Schmatz,et al.  Quantitative PCR Assay To MeasureAspergillus fumigatus Burden in a Murine Model of Disseminated Aspergillosis: Demonstration of Efficacy of Caspofungin Acetate , 2001, Antimicrobial Agents and Chemotherapy.

[21]  M. Rinaldi,et al.  Comparison of High-Performance Liquid Chromatographic and Microbiological Methods for Determination of Voriconazole Levels in Plasma , 2000, Antimicrobial Agents and Chemotherapy.

[22]  D. Denning,et al.  Practice Guidelines for Diseases Caused by Aspergillus , 2000 .

[23]  M. Ghannoum,et al.  A Head-on Comparison of the In Vitro Antifungal Activity of Conventional and Lipid-based Amphotericin B: a Multicenter Study , 2000, Journal of chemotherapy.

[24]  I. Bekersky,et al.  AmBisome (Liposomal Amphotericin B): A Comparative Review , 1998, Journal of clinical pharmacology.

[25]  D. Armstrong,et al.  Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis , 1997, Antimicrobial agents and chemotherapy.

[26]  V. Andriole,et al.  Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis , 1996, Antimicrobial agents and chemotherapy.

[27]  T. Meshulam,et al.  A simplified new assay for assessment of fungal cell damage with the tetrazolium dye, (2,3)-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanil ide (XTT). , 1995, The Journal of infectious diseases.

[28]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[29]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard , 2008 .

[30]  J. Bartlett.  Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi , 2004 .

[31]  J. Adler-Moore,et al.  AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. , 2002, The Journal of antimicrobial chemotherapy.

[32]  D. Denning,et al.  Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  A. Sugar,et al.  Effect of grapefruit juice on serum voriconazole concentrations in the mouse. , 2000, Medical mycology.

[34]  S. Piscitelli,et al.  Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. , 1998, Advances in pharmacology.

[35]  J. Adler-Moore,et al.  Development, Characterization, Efficacy and Mode of Action of Ambisome, A Unilamellar Liposomal Formulation of Amphotericin B , 1993 .

[36]  L. Pagano,et al.  Design and Methods , 2022 .